

## 2022 annual results

- Revenue: €493.5m (up 10.8%, with 5.4% like-for-like growth)
- Operating profit before non-recurring items (EBITA)<sup>(1)</sup>: €33.0m (up 8.2%), representing 6.7% of revenue
- Dividend<sup>(2)</sup>: €1.00 per share

**Paris La Défense, 14 March 2023, 5.35 p.m. (CET)** – The Board of Directors of Assystem S.A. (ISIN: FR0000074148 - ASY), an international engineering group, reviewed today the Group's financial statements for the year ended 31 December 2022.

### **Dominique Louis, Assystem's Chairman and Chief Executive Officer, stated:**

*"The need for decarbonised energy is a central preoccupation of nations, and this need has amplified following the geopolitical and climate events of 2022. Our 6,500 employees have been working for a long time now on accelerating the energy transition, and the relevance of our strategic positioning enables us, once again, to deliver a very good commercial, operational and financial performance. During the year we also successfully integrated our recent acquisitions that will help us expand our expertise clusters in order to serve our clients across the globe. We are pursuing our long-term strategic roadmap with confidence, our main challenge now being the ability to attract and retain the best talents".*

## KEY FIGURES

<i>In millions of euros (€m)</i>	<b>2021 reported</b>	<b>2021 restated*</b>	<b>2022 reported*</b>
<b>Revenue</b>	<b>483.1</b>	<b>445.4</b>	<b>493.5</b>
<b>Operating profit before non-recurring items – EBITA<sup>(1)</sup></b>	<b>32.0</b>	<b>30.5</b>	<b>33.0</b>
<i>% of revenue</i>	6.6%	6.8%	6.7%
<b>Consolidated profit for the period<sup>(3)</sup></b>	<b>34.7</b>	<b>34.7</b>	<b>49.9</b>
<b>Net debt<sup>(4)</sup></b>	<b>64.7</b>	<b>64.7</b>	<b>50.9</b>
<b>Dividend per share (in €)<sup>(2)</sup></b>	<b>1.00</b>	<b>1.00</b>	<b>1.00</b>

\*The reported figures for 2022 take into account the impacts on revenue and profit of applying IFRS 5 with regard to (i) the sale of Assystem's life sciences and general industry technical assistance activities to Expleo Group in January 2022, and (ii) the agreement entered into by Assystem to sell 51% of the shares and voting rights of MPH GS – the parent company of its Staffing business – to MPH's management. This sale took place in January 2023. The figures for 2021 have been restated accordingly in order to ensure meaningful comparisons with the figures for 2022.

(1) Operating profit before non-recurring items (EBITA - Earning Before Interest and Taxes - from Activity) including share of profit of equity-accounted investees other than Expleo Group (€0.7m in 2021 (restated) and €1.2m in 2022).

(2) Dividend for 2022 that will be recommended at the 5 June 2023 Shareholders' Meeting.

(3) Including profit attributable to non-controlling interests, amounting to €0.5m in 2021 and €1.0m in 2022. Profit for the period attributable to owners of the parent therefore totalled €34.2m in 2021 and €48.9m in 2022.

(4) Debt less cash and cash equivalents, excluding the IFRS 16 impact.

## ANALYSIS OF THE 2022 INCOME STATEMENT

- **Revenue**

**Assystem's consolidated revenue** totalled €493.5 million in 2022, up 10.8% on the €445.4 million recorded for 2021 (restated). Like-for-like growth came to 5.4%, changes in the scope of consolidation had a positive 3.9% impact (due to the consolidation of the India-based company STUP as from 1 July 2021 and the UK companies Schofield Lothian as from 1 October 2021 and LogiKal as from 1 December 2022), and the currency effect was a favourable 1.5%.

**Revenue from Nuclear activities** totalled €344.9 million in 2022 (70% of the consolidated revenue), versus €326.3 million in 2021. This 5.7% increase breaks down as 5.2% in like-for-like growth (including a 1.8% negative effect resulting from the end of the first Kacare contract) and a 0.5% favourable currency effect. Growth continued to be led throughout the year by operations in France and the United Kingdom.

**ET&I revenue** amounted to €148.6 million in 2022, compared with €119.1 million in 2021. Year-on-year growth was 24.7% (5.9% like-for-like growth, a positive 14.6% impact from changes in the scope of consolidation (consolidation of STUP, Schofield Lothian and LogiKal), and a favourable 4.2% currency effect. Like-for-like growth was led by a major new contract won in relation to the Neom project in Saudi Arabia.

- **Operating profit before non-recurring items (EBITA) and EBITDA<sup>(5)</sup>**

**Consolidated EBITA** totalled €33.0 million in 2022, up 8.2% on the €30.5 million restated figure for 2021. EBITA margin narrowed to 6.7% from 6.8% in 2021, reflecting the hiring costs incurred towards the end of 2022 to support Assystem's business growth.

**EBITA for Assystem Operations** (all of the Group's operations except for Holding activities) came to €38.5 million, representing 7.8% of revenue, compared with €36.6 million and 8.2% respectively in 2021.

The Group's "Holding company" expenses had a €5.5 million negative impact on consolidated EBITA in 2022 versus a €6.1 million negative impact in 2021.

Excluding the impact of IFRS 16, consolidated **EBITDA<sup>(5)</sup>** amounted to €39.6 million in 2022, representing 8.0% of revenue, compared with €35.8 million and 8.0% respectively in 2021 (restated).

- **Operating profit and other income statement items**

After taking into account €1.8 million in share-based payments and €1.2 million in net non-recurring expense for the period, **consolidated operating profit** totalled €30.0 million in 2022, compared with €30.2 million in 2021.

**Expleo Group** – in which Assystem holds 37.22% of the capital and 38.94% of the quasi-equity instruments issued by that company (convertible bonds with capitalised interest) – contributed €9.8 million to consolidated profit, breaking down as €11.9 million in coupons on the convertible bonds less Assystem's €2.1 million share of Expleo Group's loss for the period. In 2021, Expleo Group contributed €6.0 million, including €10.9 million in coupons on the convertible bonds.

Assystem recorded **net financial income** of €2.9 million in 2022, versus €1.6 million in 2021. The 2022 figure breaks down as €4.1 million in dividends received from Framatome (€2.4 million in 2021). It also includes €4.3 million recognised as a result of applying IAS 29 (Financial Reporting in Hyperinflationary Economies) related to the Group's Turkish subsidiary, but this had no impact on consolidated cash.

After deducting an income tax expense of €6.6 million (€7.2 million in 2021), **consolidated profit from continuing operations** rose 18.4% to €36.1 million from €30.5 million in 2021 (restated).

Profit from discontinued operations, as determined in accordance with IFRS 5, came to €13.8 million (businesses sold to Expleo and MPH classified as discontinued operations under IFRS 5).

**Consolidated profit for the period** totalled €49.9 million, versus €34.7 million in 2021.

---

<sup>(5)</sup> EBITA excluding the impact of IFRS 16 (€32.3 million in 2022) and before depreciation and amortisation expense and net provisions for non-recurring items excluding the IFRS 16 impact.

## • **Information about Expleo Group**

**Revenue generated by Expleo Group** amounted to €1.27 billion in 2022, up 23% year on year (including the Life Sciences business acquired from Assystem).

**Expleo Group's EBITDA** (including the impact of IFRS 16) surged 36% to €126 million in 2022, representing 9.9% of consolidated revenue.

**Expleo Group's consolidated profit** before recognition of the capitalised interest on its quasi-equity instruments was €31.3 million.

## **FREE CASH FLOW<sup>(6)</sup> AND NET DEBT**

**Free cash flow from continuing operations** for 2022 (excluding the impact of IFRS 16) represented a net inflow of €26.5 million, or 5.4% of consolidated revenue. For purposes of comparison, for 2020 and 2021 combined, free cash flow from continuing operations (excluding the IFRS 16 impact) represented a net inflow of €51.2 million, or 5.6% of combined revenue for those two years.

**The Group had net debt** (excluding the IFRS 16 impact) **of €50.9 million** at 31 December 2022. This was €13.8 million lower than one year earlier, breaking down as follows:

- €(26.5) million due to the impact of free cash flow from continuing operations;
- a €4.7 million impact from the free cash flow of discontinued operations;
- a €14.7 million dividend payment to Assystem shareholders for 2021;
- a €(2.9) million net-of-tax impact arising from disposals and acquisitions<sup>(7)</sup>;
- a €3.8 million net cash inflow for other movements, including €4.1 million in dividends received from Framatome and €0.1 million paid for purchases of Assystem shares.

## **RECOMMENDED DIVIDEND FOR 2022**

At the Annual General Meeting to be held on 5 June 2023, Assystem will recommend the payment of a dividend of €1.00 per share for 2022, unchanged year-on-year. If this dividend is approved by the shareholders, it would represent a total payout of €14.8 million<sup>(8)</sup>.

## **TWO NEW ACQUISITIONS CARRIED OUT IN JANUARY 2023**

Assystem is continuing its bolt-on acquisition strategy aimed at reinforcing its skills clusters in France, the United Kingdom and India. Having acquired the Anglo-Australian company LogiKal, specialised in Project Management, Assystem carried out two new external growth transactions in January (OREKA Ingénierie, specialised in digital visualisation and simulation tools, and RELSAFE PRA Consulting, specialised in nuclear safety).

## **OUTLOOK FOR 2023**

In order to complete its strategic refocusing, Assystem plans to sell its business activities in the Pacific area in 2023. In 2022, these activities generated €12.7 million in revenue, which was recognized in ET&I.

This outlook takes into account this disposal, the integration of the three acquisitions carried out since end-2022 and the impact of significant growth investments in people and competencies in 2023 to support the Group's medium-term growth. Assystem's targets for 2023 are as follows:

- consolidated revenue of between €540 million and €560 million;
- and EBITA above €33 million.

These targets are based on macroeconomic, geopolitical and health context comparable to the one in place at the beginning of the year.

<sup>(6)</sup> Corresponding to net cash generated from operating activities less capital expenditure, net of disposals.

<sup>(7)</sup> Including a net debt impact of €(26.1) million from net disposals, €19.8 million from acquisitions, and a €3.4 million impact on consolidated cash arising from the deconsolidation of MPH.

<sup>(8)</sup> Corresponding to €1.00 multiplied by the 14,839,120 outstanding shares carrying dividend rights at 28 February 2023.

## 2023 FINANCIAL CALENDAR

- 27 April: First-quarter 2023 revenue release
- 5 June: Annual General Meeting
- 25 July: First-half 2023 revenue release
- 13 September: First-half 2023 results release – Results presentation on 14 September at 8.30 a.m. (CEST)
- 26 October: Third-quarter 2023 revenue release

## ABOUT ASSYSTEM

As one of the world's leading independent nuclear engineering companies, Assystem's main mission is to help accelerate energy transition. In the 12 countries where the Group operates, the skills of its 6,500 experts are being put to the service of developing the production and use of carbon-free electricity (nuclear and renewables) as well as green hydrogen.

With over 55 years' experience in highly regulated sectors subject to stringent safety and security constraints, the Group provides engineering and digital services and solutions to optimise the cost and performance of its clients' complex infrastructure assets throughout their life cycles.

To find out more visit [www.assystem.com](http://www.assystem.com) / Follow Assystem on Twitter: @Assystem

## CONTACTS

**Malène Korvin** – Chief Financial Officer - [mkorvin@assystem.com](mailto:mkorvin@assystem.com) - Tel.: +33 (0)1 41 25 29 00

**Anne-Charlotte Dagorn** – Communications Director – [acdagorn@assystem.com](mailto:acdagorn@assystem.com) - Tel.: +33 (0)6 83 03 70 29

**Agnès Villeret – Komodo** – Investor relations - [agnes.villeret@agence-komodo.com](mailto:agnes.villeret@agence-komodo.com) – Tel.: +33 (0)6 83 28 04 15

## APPENDICES

### 1/ REVENUE AND EBITA BY BUSINESS

In millions of euros	2021 reported	2021 restated <sup>(1)</sup>	2022 reported	Total year-on-year change <sup>(2)</sup>	Like-for-like change <sup>(2,3)</sup>
<b>Group</b>	<b>483.1</b>	<b>445.4</b>	<b>493.5</b>	<b>+10.8%</b>	<b>+5.4%</b>
Nuclear	326.3	326.3	344.9	+5.7%	+5.2%
ET&I <sup>(4)</sup>	156.8	119.1	148.6	+24.7%	+5.9%

(1) Restated to enable meaningful year-on-year comparisons.

(2) Compared with restated 2021 data.

(3) Based on a comparable scope of consolidation and constant exchange rates.

(4) UK-based LogiKal consolidated since 1 December 2022.

### • EBITA<sup>(5)</sup>

In millions of euros	2021 restated	% of revenue	2022 reported	% of revenue
<b>Group</b>	<b>30.5</b>	<b>6.8%</b>	<b>33.0</b>	<b>6.7%</b>
Assystem Operations	<b>36.6</b>	8.2%	<b>38.5</b>	7.8%
Holding company and Other	<b>(6.1)</b>	-	<b>(5.5)</b>	

(5) Operating profit before non-recurring items (EBITA) including share of profit of equity-accounted investees other than Expleo Group (€0.7 million in 2021 and €1.2m in 2022).

## 2/ CONSOLIDATED FINANCIAL STATEMENTS

### • CONSOLIDATED STATEMENT OF FINANCIAL POSITION

<i>In millions of euros</i>	31 Dec. 2021	31 Dec. 2022
<b>ASSETS</b>		
Goodwill	97.0	122.2
Intangible assets	4.4	3.6
Property, plant and equipment	12.9	11.7
Right-of-use assets	33.2	30.6
Investment property	1.3	1.3
Equity-accounted investees	1.0	1.4
Expleo Group shares	41.3	37.1
Expleo Group convertible bonds	132.3	144.2
Expleo Group shares and convertible bonds	173.6	181.3
Other non-current financial assets <sup>(1)</sup>	147.7	141.3
Deferred tax assets	8.8	8.3
<b>Non-current assets</b>	<b>479.9</b>	<b>501.7</b>
Trade receivables	169.3	163.6
Other receivables	27.7	23.8
Income tax receivables	3.4	4.2
Other current assets	0.3	1.3
Cash and cash equivalents <sup>(2)</sup>	25.7	28.5
Assets classified as held for sale	18.3	16.3
<b>Current assets</b>	<b>244.7</b>	<b>237.7</b>
<b>TOTAL ASSETS</b>	<b>724.6</b>	<b>739.4</b>
<b>EQUITY AND LIABILITIES</b>	<b>31 Dec. 2021</b>	<b>31 Dec. 2022</b>
Share capital	15.7	15.7
Consolidated reserves	307.3	334.8
Profit for the period attributable to owners of the parent	34.2	48.9
<b>Equity attributable to owners of the parent</b>	<b>357.2</b>	<b>399.4</b>
Non-controlling interests	1.3	2.1
<b>Total equity</b>	<b>358.5</b>	<b>401.5</b>
Long-term debt and non-current financial liabilities <sup>(2)</sup>	89.8	76.0
Non-current lease liabilities	26.5	24.7
Pension and other employee benefit obligations	22.4	19.3
Long-term provisions	16.3	17.0
Deferred tax liabilities	0.1	0.4
<b>Non-current liabilities</b>	<b>155.1</b>	<b>137.4</b>
Short-term debt and current financial liabilities <sup>(2)</sup>	0.5	3.4
Current lease liabilities	8.2	7.6
Trade payables	34.8	35.3
Due to suppliers of non-current assets	0.2	0.1
Accrued taxes and payroll costs	107.2	98.8
Income tax liabilities	2.2	3.3
Short-term provisions	2.6	3.3
Other current liabilities	46.3	42.4
Liabilities directly associated with assets classified as held for sale	9.0	6.3
<b>Current liabilities</b>	<b>211.0</b>	<b>200.5</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>724.6</b>	<b>739.4</b>

(1) Including Framatome shares, representing €134.0 million at 31 December 2022.

(2) Net debt totalled €50.9 million at 31 December 2022, breaking down as:

- Short- and long-term debt and current and non-current financial liabilities: €79.4 million
- Cash and cash equivalents: €28.5 million.

• **CONSOLIDATED INCOME STATEMENT**

<i>In millions of euros</i>	<b>2021 restated</b>	<b>2022 reported</b>
<b>Revenue</b>	<b>445.4</b>	<b>493.5</b>
Payroll costs	(308.1)	(343.2)
Other operating income and expenses	(91.9)	(101.1)
Taxes other than on income	(0.8)	(1.1)
Depreciation, amortisation and provisions for recurring operating items, net	(14.8)	(16.3)
<b>Operating profit before non-recurring items (EBITA)</b>	<b>29.8</b>	<b>31.8</b>
Share of profit of equity-accounted investees	0.7	1.2
<b>EBITA including share of profit of equity-accounted investees</b>	<b>30.5</b>	<b>33.0</b>
Non-recurring income and expenses	1.2	(1.2)
Share-based payments	(1.5)	(1.8)
<b>Operating profit</b>	<b>30.2</b>	<b>30.0</b>
Share of profit/(loss) of Expleo Group	(4.9)	(2.1)
Income from Expleo Group convertible bonds	10.9	11.9
Net financial income/(expense) on cash and debt	0.3	(1.5)
Other financial income and expenses	1.2	4.4
<b>Profit from continuing operations before tax</b>	<b>37.7</b>	<b>42.7</b>
Income tax expense	(7.2)	(6.6)
<b>Profit from continuing operations</b>	<b>30.5</b>	<b>36.1</b>
Profit from discontinued operations	4.2	13.8
<b>Consolidated profit for the period</b>	<b>34.7</b>	<b>49.9</b>
Attributable to:		
Owners of the parent	34.2	48.9
Non-controlling interests	0.5	1.0

• **CONSOLIDATED STATEMENT OF CASH FLOWS**

<i>In millions of euros</i>	<b>2021 restated</b>	<b>2022 reported</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
EBITA including share of profit of equity-accounted investees	30.5	33.0
Depreciation, amortisation and provisions for recurring operating items, net	14.8	16.3
<b>EBITDA</b>	<b>45.3</b>	<b>49.3</b>
Change in operating working capital requirement	(27.2)	(4.3)
Income tax paid	(6.7)	(5.9)
Other cash flows	(4.0)	1.0
Net cash generated from/(used in) operating activities of discontinued operations	4.5	(4.6)
<b>Net cash generated from operating activities</b>	<b>11.9</b>	<b>35.5</b>
<i>O/w: - continuing operations</i>	7.4	40.1
<i>- discontinued operations</i>	4.5	(4.6)
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Acquisitions of property, plant and equipment and intangible assets, net of disposals – continuing operations, o/w:	(4.9)	(3.9)
<i>Acquisitions of property, plant and equipment and intangible assets</i>	(5.0)	(4.0)
<i>Proceeds from disposals of property, plant and equipment and intangible assets</i>	0.1	0.1
<b>Free cash flow</b>	<b>7.0</b>	<b>31.6</b>
<i>O/w: - continuing operations</i>	2.5	36.2
<i>- discontinued operations</i>	4.5	(4.6)
Acquisitions of shares and businesses	(23.8)	(19.8)
Other movements, net	2.4	6.1
Net cash generated from/(used in) investing activities – discontinued operations	(0.3)	25.9
<b>Net cash generated from/(used in) investing activities</b>	<b>(26.6)</b>	<b>8.3</b>
<i>O/w: - continuing operations</i>	(26.3)	(17.6)
<i>- discontinued operations</i>	(0.3)	25.9
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Net financial income received/(expenses paid)	(0.6)	(2.8)
Proceeds from new borrowings	24.0	-
Repayments of borrowings and movements in other financial liabilities	(2.0)	(12.0)
Repayments of lease liabilities*	(10.1)	(9.8)
Dividends paid	(14.7)	(14.7)
Other movements in equity of the parent company	(1.4)	(0.1)
<b>Net cash generated from/(used in) financing activities</b>	<b>(4.8)</b>	<b>(39.4)</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>(19.5)</b>	<b>4.4</b>

\* Including interest expense.

### 3/ MOVEMENTS IN NET DEBT

<i>In millions of euros - EXCLUDING IFRS 16 IMPACT</i>		
<b>Net debt at 31 Dec. 2021</b>	<b>64.7</b>	
Free cash flow from continuing operations	(26.5)	
Free cash flow from discontinued operations	4.7	
Dividends paid to Assystem shareholders	14.7	
Net tax effect of disposals and acquisitions in 2022	(2.9)	
Other movements	(3.8)	<i>Including €(4.1) million in dividends received from Framatome</i>
<b>Net debt at 31 Dec. 2022</b>	<b>50.9</b>	

### 4/ INFORMATION ABOUT THE COMPANY'S CAPITAL

<b>NUMBER OF SHARES</b>	<b>At 31 Dec. 2021</b>	<b>At 31 Dec. 2022</b>
Ordinary shares outstanding	15,668,216	15,668,216
Treasury shares	876,771	833,400
Free shares and performance shares outstanding	216,300	268,425
Weighted average number of shares outstanding	14,776,162	14,812,512
Weighted average number of diluted shares	14,492,462	15,080,937

### OWNERSHIP STRUCTURE AT 28 FEBRUARY 2023

<b>In %</b>	<b>Shares</b>	<b>Exercisable voting rights</b>
HDL Development <sup>(1)</sup>	57.93%	74.79%
Free float <sup>(2)</sup>	36.78%	25.21%
Treasury shares	5.29%	-

(1) HDL Development is a holding company that is 91.22%-controlled by Dominique Louis (Assystem's Chairman and Chief Executive Officer), notably through HDL, which itself holds 0.85% of Assystem's capital.

(2) Including 0.85% held by HDL.